Since damage-associated molecular patterns associated with immunogenic cell death CD were significantly elevated in URCCA4.3 tumors treated with combination therapy, we also investigated the dynamics of the tumor immune microenvironment in response to pan-LOX inhibition. The gene discussed is LOX; the disease is neoplasm.